CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024 .
Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time . Details for the call are as follows: Wednesday, November 13th @ 4:30 pm Eastern Time / 1:30 pm Pacific Time Toll Free: 1-877-407-0784 International: 1-201-689-8560 Call Me: https://callme.viavid.
com/viavid/?callme=true&passcode=13740526&h=true&info=company -email&r=true&B=6 Participants can use guest dial-in numbers above to reach an operator or they can click the Call me TM link for instant telephone access to the event (dial-out). The Call meTM link will be made active 15 minutes prior to the scheduled start time. Webcast: https://viavid.
webcasts.com/starthere.jsp?ei=1691806&tp_key=491002eb9b About DURECT Corporation DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury.
Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of D.